Premium
The Use of the Prostaglandin Synthetase Inhibitor Mefenamic Acid in the Treatment of Menorrhagia
Author(s) -
Jakubowicz Diana L.,
Wood Carl
Publication year - 1978
Publication title -
australian and new zealand journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.734
H-Index - 65
eISSN - 1479-828X
pISSN - 0004-8666
DOI - 10.1111/j.1479-828x.1978.tb00031.x
Subject(s) - mefenamic acid , placebo , medicine , menstruation , blood loss , incidence (geometry) , clinical trial , prostaglandin , randomized controlled trial , gastroenterology , pharmacology , anesthesia , surgery , optics , physics , alternative medicine , pathology
Summary: A randomized, controlled, double‐blind clinical trial was conducted to compare the effect of the prostaglandin synthetase inhibitor mefenamic acid (Ponstan) given during menstruation to that of a placebo in the treatment of menorrhagia. A statistically significant reduction in menstrual blood loss was recorded by 14 of 15 patients in the mefenamic acid group. The incidence of side effects was minimal. Placebo therapy was significantly more effective than no therapy. Further exploration of the use of mefenamic acid in patients with excessive menstrual loss is recommended.